AI주식인사이트AI Stock Insight
C

샤페론

378800KOSDAQ기초 의약물질 제조업

47.9 / 100

Reference Date: 2026-07-24

Financial Score19.5 / 40
News Sentiment19.4 / 25
Momentum2.0 / 20
Disclosure7.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but Operating Profit is on a declining trend. Plunged 51.5% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Shapieron is a biotech venture specializing in drug development, leveraging its platform targeting GPCR19 to inhibit inflammatory complexes. The company is conducting clinical trials for COVID-19 and Alzheimer's treatments, while expanding into ADC and RPT-based nanobody development. It has established a U.S. subsidiary and demonstrated commercialization capabilities through two technology transfers.

Number of Employees

53people

Average Salary

71.3M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 25.444.0Point
PBR
0.98Industry Average 1.264.0Point

In line with industry avg

ROE
-76.22Industry Average -6.033.5Point

12.6x industry avg (excellent)

Debt Ratio
4.65Industry Average 6.625.0Point

Lower than industry avg (good)

Trend 2023~20253.0 / 10 points
Revenue Growth Rate
3.0 / 3

Avg ▲547.5% (2-year basis)

Operating Profit Growth Rate
0.0 / 3

Avg ▼9.5% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -70.9% (declining, 3yr)

Detailed News Sentiment

13 totalPositive 9Neutral 1Negative 3Average Sentiment Score 77.7

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 526Won52-week high 2,95552-week low 503
1-month return0.0Point

1m -51.48% (strong drop)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

6 totalPositive 0Neutral 5Negative 1
  • Neutral의결권대리행사권유참고서류2026-07-22
  • Neutral주주총회소집공고2026-07-22
  • Negative불성실공시법인지정예고 (공시불이행)2026-07-09
  • Neutral[기재정정]주식병합결정2026-07-07
  • Neutral주식등의대량보유상황보고서(일반)2026-06-30